ProShares Ultra Health Care (RXL) 最新ニュース、市場動向および感情 | Edgen
戻る
ホーム
株式
RXL
ProShares Ultra Health Care (RXL)
RXL 株価推移チャート
RXL
ProShares Ultra Health Care
$56.59
-1.27%
$-0.72
終値: Sep 10, 16:00:00 GMT-4
$56.59
0%
$0
アフターマーケット:Sep 10, 20:00:00 GMT-4
概要
予測
保有株式
ニュース
記事
主要データ
前終値
$57.32
始値
$56.96
当日レンジ
$56.55 - $57.47
52週レンジ
$39.32 - $64.59
取引高
6.0K
平均取引高
11.1K
配当利回り
1.55%
純資産
$0
NAV
--
費用率
--
発行済株式数
1.5M
RXLとは何ですか?
RXL was created on 2007-01-30 by ProShares. The fund's investment portfolio concentrates primarily on health care equity. RXL provides 2x leveraged exposure to a cap-weighted index of US health care companies.
特徴
株式・暗号通貨用AIコピローター
価格予測
資金調達トラッカー
暗号通貨比較
ホームページ
Markets
US Stocks
HK Stocks
Crypto
News
Analyst Moves
Market Moves
Hong Kong IPO
Earnings
AI & Technology
Macro & Policy
利用規約
プライバシーポリシー
サイトマップ
© 2026 Edgen によって提供
Merck lifts pipeline target to $70B as KEYTRUDA cliff nears
Sep 10 2026, 10:37
Amgen falls 10% as Novartis Lp(a) trial failure clouds drug class
Sep 08 2026, 17:27
Moderna-Merck vaccine clears Phase 3, stock jumps 177% on melanoma data
Sep 06 2026, 18:55
Viking Therapeutics trades below targets as VK2735 oral safety questioned
Sep 06 2026, 00:57
Gilead's third FDA approval in 4 months lifts turnaround case
Sep 05 2026, 16:28
AbbVie closes $10.9B Apogee deal to expand immunology pipeline
Sep 03 2026, 13:01
Ivonescimab beats Keytruda on survival in 4th phase 3 win
Sep 02 2026, 22:28
Moderna stock doubles in August after melanoma trial win with Merck
Sep 01 2026, 11:27
Lilly Taltz-Zepbound combo sustains 30.6% skin-clearance goal at 52 weeks
Aug 31 2026, 14:34
Eli Lilly to buy Merida Biosciences for up to $2.875 billion
Aug 31 2026, 14:14
Amgen's Repatha cuts death risk 20% in high-risk primary prevention trial
Aug 31 2026, 12:24
Moderna stock surges 127% as cancer vaccine reshapes biotech outlook
Aug 30 2026, 17:52
Eli Lilly GLP-1 sales surge 48% as employer coverage falls to 60%
Aug 28 2026, 20:22
FDA approves Lilly's Mounjaro to cut cardiovascular risk 8%
Aug 28 2026, 12:35
Gilead's Bixlenvo wins FDA approval as first single-tablet HIV option
Aug 27 2026, 22:26
Pfizer, BioNTech win FDA approval for XFG COVID vaccine, 5B doses
Aug 27 2026, 20:54
FDA clears Roche, Eli Lilly Alzheimer's blood test for 55-plus patients
Aug 27 2026, 15:55
Tezspire meets EoE trial goals, expanding to 470,000 US patient pool
Aug 27 2026, 10:27